Corbus Appoints Ex-BMS Oncology Head Pfeiffenberger to Drive CRB-701 Registration Study
Corbus Pharmaceuticals has named Brent Pfeiffenberger, former Neogene COO and ex-Bristol Myers Squibb Oncology head, to its board to strengthen commercial and development strategy ahead of a CRB-701 registrational trial in second-line head and neck cancer this summer. Updated CRB-701 Phase 1/2 data will be unveiled at ASCO’s May 29 – June 2 meeting.
1. Board Appointment and Strategic Rationale
Corbus Pharmaceuticals has added Brent Pfeiffenberger to its Board of Directors to enhance leadership in commercial strategy and clinical development. His appointment aligns with the company’s plan to initiate a CRB-701 registrational study in second-line head and neck squamous cell carcinoma this summer.
2. Pfeiffenberger’s Pharma Industry Experience
Dr. Pfeiffenberger currently leads Century Therapeutics as CEO and chairs its board. He previously served as COO of Neogene Therapeutics, guiding its transition to a global clinical-stage firm acquired by AstraZeneca, and spent nearly 20 years at Bristol Myers Squibb overseeing U.S. Oncology operations and global commercial oncology strategy.
3. Upcoming CRB-701 Milestones
Corbus recently achieved broad FDA alignment on the registration path for CRB-701 in head and neck cancer. The company expects to initiate a registrational trial in second-line HNSCC this summer and will present updated Phase 1/2 data at the ASCO Annual Meeting scheduled for May 29 – June 2.
4. CRB-913 Phase 1b Study Status
The CANYON-1 Phase 1b dose-ranging trial of CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, is enrolling 240 patients across a 16-week protocol. Corbus projects completion of this study in summer 2026, maintaining its clinical timeline for obesity program development.